Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Novartis creates public portal for cancer knockdown data

Novartis AG (NYSE:NVS; SIX:NOVN) published its large-scale Project DRIVE cancer study online in Cell Thursday, outlining the results of nearly 8,000 gene knockdowns in roughly 400 patient derived cancer cell lines. The publication -- the first of this scale for gene

Read the full 413 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers